{"clinical_study": {"@rank": "233", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04329546"}, "id_info": {"org_study_id": "2020-00516", "nct_id": "NCT04329546"}, "brief_title": "Understanding COVID", "official_title": "How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study", "sponsors": {"lead_sponsor": {"agency": "University Hospital, Geneva", "agency_class": "Other"}, "collaborator": {"agency": "University of Geneva, Switzerland", "agency_class": "Other"}}, "source": "University Hospital, Geneva", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "This single-center prospective observational study will examine immune responses to to\n      SARS-CoV-2 and how they correlate with its virological characteristics and clinical\n      manifestations in infected patients. Household contacts will also be included so that early\n      immune responses and viral kinetics can be captured. Patients and contacts will be followed\n      for 8 and 2 weeks, respectively. The study will include a maximum of 250 participants."}, "detailed_description": {"textblock": "The primary aim of this single-center prospective observational study is to establish how\n      immune responses to SARS-CoV-2 or to cross-reactive viruses correlate with the virological\n      and clinical characteristics of SARS- CoV-2-infected patients and their exposed household\n      contacts. Through iterative sampling, the viral kinetics of at least 50 infected patients\n      will be evaluated in relation to symptom severity and innate and adaptive immune responses,\n      while their household contacts will be observed for viral detection and immune responses.\n      Patients and contacts will be followed for 8 and 2 weeks, respectively. The study will\n      include a maximum of 250 participants."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "March 27, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "March 31, 2022"}, "primary_completion_date": {"@type": "Anticipated", "#text": "January 31, 2022"}, "study_type": "Observational", "has_expanded_access": "No", "study_design_info": {"observational_model": "Cohort", "time_perspective": "Prospective"}, "primary_outcome": [{"measure": "Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days", "time_frame": "assessed at 28 days after diagnosis/presumed diagnosis", "description": "Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days after diagnosis/suspected diagnosis"}, {"measure": "Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis", "time_frame": "56 days after diagnosis/presumed diagnosis", "description": "Peak viral load in the 56 days following diagnosis/suspected diagnosis, quantified by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs."}], "number_of_groups": "2", "enrollment": {"@type": "Anticipated", "#text": "250"}, "condition": "SARS-CoV-2 Viral Kinetics and Host Immune Responses", "arm_group": [{"arm_group_label": "Cases", "description": "Cases are patients with COVID-19."}, {"arm_group_label": "Contacts", "description": "Contacts are household contacts of an index (case) patient."}], "intervention": {"intervention_type": "Other", "intervention_name": "NA (no intervention)", "description": "NA (no intervention)", "arm_group_label": ["Cases", "Contacts"]}, "biospec_retention": "Samples With DNA", "biospec_descr": {"textblock": "naso- & oro-pharyngeal smears, sputum, blood"}, "eligibility": {"study_pop": {"textblock": "Adults and children of all ages either infected with, or presumed to be infected with\n        SARS-CoV-2, and their household contacts."}, "sampling_method": "Non-Probability Sample", "criteria": {"textblock": "Inclusion Criteria:\n\n        The following persons may be included:\n\n          -  A patient of any age meeting the European Centre for Disease Control and Prevention's\n             confirmed case definition: \"A person with laboratory confirmation of virus causing\n             COVID-19, irrespective of clinical signs and symptoms\" (and/or high suspicion/actively\n             being treated as CoVID+ cases pending test confirmation)\n\n          -  Household contacts (defined as those sleeping in the same apartment/house as an\n             infected patient) of a patient with laboratory-confirmed COVID-19 (and/or high\n             suspicion/actively being treated as CoVID+ cases pending test confirmation), whether\n             symptomatic or not, and whether testing positive or not during a period of 14 days\n\n        Exclusion Criterion:\n\n          -  Long-term incapacity leading to the inability to provide informed consent while not\n             having a patient representative with the ability to provide informed consent"}, "gender": "All", "gender_based": "Yes", "minimum_age": "N/A", "maximum_age": "N/A"}, "overall_official": {"last_name": "Claire-Anne Siegrist, MD", "role": "Principal Investigator", "affiliation": "Professor of vaccinology"}, "overall_contact": {"last_name": "Claire-Anne Siegrist, MD", "phone": "+41795533396", "email": "claire-anne.siegrist@unige.ch"}, "overall_contact_backup": {"last_name": "Angela Huttner, MD", "phone": "+41795533396", "email": "angela.huttner@hcuge.ch"}, "location": {"facility": {"name": "University Hospitals of Geneva", "address": {"city": "Geneva", "zip": "1211", "country": "Switzerland"}}, "status": "Recruiting", "contact": {"last_name": "Claire-Anne Siegrist, MD", "phone": "+4179 553 4676"}, "investigator": {"last_name": "Claire-Anne Siegrist, MD", "role": "Principal Investigator"}}, "location_countries": {"country": "Switzerland"}, "verification_date": "March 2020", "study_first_submitted": "March 29, 2020", "study_first_submitted_qc": "March 29, 2020", "study_first_posted": {"@type": "Actual", "#text": "April 1, 2020"}, "last_update_submitted": "March 29, 2020", "last_update_submitted_qc": "March 29, 2020", "last_update_posted": {"@type": "Actual", "#text": "April 1, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "University Hospital, Geneva", "investigator_full_name": "Siegrist Claire-Anne", "investigator_title": "Professor of vaccinology"}, "patient_data": {"sharing_ipd": "Undecided", "ipd_description": "Fully anonymized data that are not already published may be shared on reasonable request from a qualified investigator, at the discretion of the Project Leader."}}}